GenSight’s second LHON gene therapy PhIII stumbles out of the gate — just like the first time
However GenSight’s gene therapy for Leber hereditary optic neuropathy works, it clearly has no significant effect at 48 weeks. But that doesn’t mean the biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
